Evaluation of two lithium carbonate formulations

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Formulation

Background:

• Lithium carbonate is a standard treatment for bipolar disorder.
• Assessing the bioavailability of different lithium carbonate formulations is crucial for therapeutic equivalence.
• New drug delivery systems aim to improve patient compliance and therapeutic outcomes.

Purpose of the Study:

• To compare the bioavailability of a new capsular formulation of lithium carbonate (Pfi-Lithium) against a standard formulation (Eskalith).
• To determine if Pfi-Lithium demonstrates equivalent pharmacokinetic properties to Eskalith.

Main Methods:

• An open-label, two-way crossover study with a Latin-square design was employed.
• Eighteen healthy adult male volunteers participated in the study.
• Serial blood samples were collected after administering a 300-mg dose of each lithium carbonate formulation for pharmacokinetic analysis.

Main Results:

• No statistically significant differences were observed between the two formulations in terms of peak plasma concentration.
• Time to peak plasma concentration did not significantly differ between Pfi-Lithium and Eskalith.
• Area under the plasma concentration-time curve (AUC) showed no significant variation, indicating comparable overall drug exposure.

Conclusions:

• The single-dose study suggests that Pfi-Lithium is bioequivalent to the standard Eskalith formulation.
• The findings support the potential interchangeability of Pfi-Lithium with Eskalith in clinical practice.
• Further studies may be warranted to confirm long-term efficacy and safety profiles.